STOCK TITAN

Taysha Gene Therapies Added to the ICE Biotechnology Index

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Taysha Gene Therapies (NASDAQ: TSHA) has been added to the ICE Biotechnology Index (NYSE: ICEBIO), effective December 20, 2021. This inclusion recognizes its value and platform in the biotechnology sector, focusing on gene therapies for central nervous system disorders. CEO RA Session II emphasized the importance of this validation as the company works towards clinical and regulatory milestones to enhance visibility within the investment community. The ICE Biotechnology Index tracks U.S.-listed biotech companies engaged in therapeutic research and development.

Positive
  • Inclusion in the ICE Biotechnology Index provides validation for Taysha's platform.
  • The company's focus on clinical and regulatory milestones may enhance investor visibility.
Negative
  • None.

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been added to the ICE Biotechnology Index (NYSE:ICEBIO) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.

“Taysha’s inclusion in this key biotechnology index provides important validation of our platform and value proposition as a company,” said RA Session II, President, Founder and CEO of Taysha. “We remain focused on executing our near-term clinical and regulatory milestones, which we believe will continue to increase our visibility within the investment community.”

The ICE Biotechnology Index tracks the performance of qualifying U.S.-listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.

FAQ

What is the significance of Taysha Gene Therapies being added to the ICE Biotechnology Index?

Taysha's addition to the ICE Biotechnology Index recognizes its value in the biotechnology sector and may increase investor interest.

When did Taysha Gene Therapies join the ICE Biotechnology Index?

Taysha Gene Therapies was added to the ICE Biotechnology Index effective December 20, 2021.

What is Taysha Gene Therapies focusing on?

Taysha Gene Therapies is focused on developing AAV-based gene therapies for monogenic diseases of the central nervous system.

Who is the CEO of Taysha Gene Therapies?

RA Session II is the President and CEO of Taysha Gene Therapies.

What types of companies are included in the ICE Biotechnology Index?

The ICE Biotechnology Index includes U.S.-listed biotech companies involved in therapeutic research and development.

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Stock Data

417.06M
204.94M
17.54%
78.21%
10.1%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DALLAS